2017-0204 - Suspension - Abattis Bioceuticals Corp. (ATT)
February 6, 2017
Abattis Bioceuticals Corp. is in default of CSE requirements. Effective immediately, Abattis Bioceuticals will be suspended pursuant to CSE Policy 3. The suspension is considered a Regulatory Halt as defined in National Instrument 23-101 Trading Rules. A cease trade order has been issued by the British Columbia Securities Commission and the Ontario Securities Commission.
Date: Effective immediately, February 6, 2017
If you have any questions or require further information please contact Listings at (416) 367-7340 or E-mail: Listings@thecse.com